Heart Test Laboratories Inc (HSCS) Stock Price, Quote & News

Company Profile

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventi...

Industry: Medical Devices

Sector: Healthcare

Phone: 682 237 7781

Website: heartsciences.com

Address:

550 Reserve Street, Suite 360, Southlake, United States

RyaKelly Feb. 2 at 6:26 PM

$HSCS biotech microcap low attention needs catalyst plus volume

0 · Reply

DrTampa Feb. 2 at 9:25 AM

$HSCS Y'all ready to make the donuts? Drop that news Simpson and make that DOHHH 🤑🤑🤑

1 · Reply

Moneyybaggs Jan. 30 at 2:46 PM

$HSCS An endorsement is not a contract that generates revenue. PR was essentially a NOTHING BURGER. Now if that PR had said 50 of those 123 hospitals were onboard then the SP is off to the races BUT IT DIDN’T!!! Clearly HSCS is having difficulty getting hospitals to sign on the dotted line so maybe the technology isn’t the game changer we thought it was because nobody seems to be rushing to deploy HSCS’s technology. Here’s a question I’d like to know the answer to - has Mt. Sinai Hospital deployed the MyoVista Insight’s technology since HSCS has that development agreement with Mt. Sinai which has been in place for several years. It would be VERY TELLING if they haven’t. You can have the best technology in the world but if nobody adopts it then it doesn’t matter!!!

1 · Reply

14745Barclay Jan. 30 at 1:57 PM

$HSCS This tepid response from the market is not what I was expecting.

0 · Reply

DrTampa Jan. 30 at 5:30 AM

$HSCS more institutional buying reported 🤑 newest filing reports as of yesterday!

0 · Reply

JuliVeytsman Jan. 30 at 1:39 AM

$HSCS The company is targeting FDA submission for a cloud-based algorithm for detecting reduced ejection fraction in the first half of 2026

1 · Reply

DrTampa Jan. 29 at 9:38 PM

$HSCS well well well, we have news of our first large hospital system signing on to use MyoVista Insight SASS platform! $10,000 from each hospital would be $1,230,000 in yearly revenue, so needless to say my tits are jacked! Wen FDA approval? https://ir.heartsciences.com/pr/cibolo-health-designates-heartsciences-myovista-insights-as-endorsed-ecg-management-platform-for-network-of-123-independent-hospitals

0 · Reply

DrTampa Jan. 28 at 9:05 AM

$HSCS You already make the donuts? Drop the news Simpson!

1 · Reply

DrTampa Jan. 28 at 4:32 AM

$HSCS short shares are down as of 1/16/26 reporting that was published today 🫡

0 · Reply

BillionerOfKing Jan. 27 at 11:52 PM

$HSCS Current Stock Price: $3.41

0 · Reply

Cibolo Health Designates HeartSciences' MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals

Dec 15, 2025, 4:15 PM EST - 7 weeks ago

HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Dec 15, 2025, 8:30 AM EST - 7 weeks ago

HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device

Dec 11, 2025, 8:30 AM EST - 7 weeks ago

HeartSciences Announces Major Upgrade to User Features of MyoVista Insights Platform with Commercial Launch Version 1.1

Sep 11, 2025, 4:15 PM EDT - 5 months ago

HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

Aug 15, 2025, 9:00 AM EDT - 6 months ago

HeartSciences Announces Conference Participation and Investor Webinar

Jul 24, 2025, 4:15 PM EDT - 6 months ago

HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

Jun 4, 2025, 9:00 AM EDT - 8 months ago

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Jun 3, 2025, 9:00 AM EDT - 8 months ago

Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value

May 29, 2025, 9:00 AM EDT - 8 months ago

HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

May 20, 2025, 9:00 AM EDT - 9 months ago

HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

May 8, 2025, 9:00 AM EDT - 9 months ago

HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

May 7, 2025, 9:00 AM EDT - 9 months ago

HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

May 1, 2025, 9:00 AM EDT - 9 months ago

HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program

Mar 13, 2025, 4:15 PM EDT - 11 months ago

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

Mar 10, 2025, 9:00 AM EDT - 11 months ago

HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

Dec 16, 2024, 4:15 PM EST - 1 year ago

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

Nov 13, 2024, 9:00 AM EST - 1 year ago

HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

Oct 14, 2024, 4:15 PM EDT - 1 year ago

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 12, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

Sep 12, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

Jul 29, 2024, 4:05 PM EDT - 1 year ago

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Jul 26, 2024, 9:00 AM EDT - 1 year ago

Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

Jul 25, 2024, 8:30 AM EDT - 1 year ago

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

Jul 11, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

Jun 4, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Regains Compliance with Nasdaq Listing Requirements

May 20, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

Apr 24, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Apr 2, 2024, 4:15 PM EDT - 2 years ago

HeartSciences to Present at the LD Micro Invitational XIV Conference

Mar 26, 2024, 9:00 AM EDT - 2 years ago

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Mar 14, 2024, 4:15 PM EDT - 2 years ago

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Mar 12, 2024, 9:00 AM EDT - 2 years ago

HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

Mar 6, 2024, 9:00 AM EST - 2 years ago

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

Feb 26, 2024, 9:00 AM EST - 2 years ago

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Feb 12, 2024, 9:00 AM EST - 2 years ago

HeartSciences Expands its Scientific Advisory Board

Feb 1, 2024, 9:00 AM EST - 2 years ago

HeartSciences Appoints New Scientific Advisory Board Member

Jan 18, 2024, 8:00 AM EST - 2 years ago

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

Jan 3, 2024, 4:15 PM EST - 2 years ago

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

Dec 14, 2023, 4:15 PM EST - 2 years ago

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

Dec 5, 2023, 8:00 AM EST - 2 years ago

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

Nov 13, 2023, 8:45 AM EST - 2 years ago

HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

Nov 3, 2023, 8:28 AM EDT - 2 years ago

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

ARQT SINT

Sep 14, 2023, 4:15 PM EDT - 2 years ago

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

Sep 12, 2023, 4:15 PM EDT - 2 years ago

HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

Sep 11, 2023, 4:15 PM EDT - 2 years ago

HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards

Sep 7, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India

Aug 31, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

Aug 24, 2023, 9:00 AM EDT - 2 years ago

HeartSciences' MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

Aug 17, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

Jul 27, 2023, 9:00 AM EDT - 2 years ago

MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark

RyaKelly Feb. 2 at 6:26 PM

$HSCS biotech microcap low attention needs catalyst plus volume

0 · Reply

DrTampa Feb. 2 at 9:25 AM

$HSCS Y'all ready to make the donuts? Drop that news Simpson and make that DOHHH 🤑🤑🤑

1 · Reply

Moneyybaggs Jan. 30 at 2:46 PM

1 · Reply

14745Barclay Jan. 30 at 1:57 PM

$HSCS This tepid response from the market is not what I was expecting.

0 · Reply

DrTampa Jan. 30 at 5:30 AM

$HSCS more institutional buying reported 🤑 newest filing reports as of yesterday!

0 · Reply

JuliVeytsman Jan. 30 at 1:39 AM

$HSCS The company is targeting FDA submission for a cloud-based algorithm for detecting reduced ejection fraction in the first half of 2026

1 · Reply

DrTampa Jan. 29 at 9:38 PM

0 · Reply

DrTampa Jan. 28 at 9:05 AM

$HSCS You already make the donuts? Drop the news Simpson!

1 · Reply

DrTampa Jan. 28 at 4:32 AM

$HSCS short shares are down as of 1/16/26 reporting that was published today 🫡

0 · Reply

BillionerOfKing Jan. 27 at 11:52 PM

$HSCS Current Stock Price: $3.41

0 · Reply

twib Jan. 27 at 12:42 PM

$HSCS Looking good! Pos here, pos that I'll get all my $ back and be pos:) Getting da.. close

0 · Reply

DrTampa Jan. 26 at 2:39 AM

$HSCS Drop the Myovista Insight News so we can make the DOHHH go nuts, Simpson! LFGGG!

0 · Reply

Moneyybaggs Jan. 23 at 12:56 PM

$HSCS I see where @DrTampa bought 1 share this morning to get the festivities started!🤣 It’s time to make the donuts. We need to take out that supply of stock that is for sale between $3.60-3.70. This stock rolls after that resistance is taken out. Crazy

1 · Reply

Moneyybaggs Jan. 22 at 5:04 PM

$HSCS RELEASE THE HOUNDS!!!

0 · Reply

DrTampa Jan. 22 at 5:03 PM

$HSCS posted the wrong photo yesterday lol here's what I was busy grabbing at market close yesterday! Can we see $4 before end of this week?!?

0 · Reply

Moneyybaggs Jan. 22 at 4:57 PM

$HSCS We need that catalyst Simpson. GIVE IT TO US!!!

0 · Reply

JuliVeytsman Jan. 22 at 3:43 PM

$HSCS 3,86 this morning 🙌

0 · Reply

TheUnmaker Jan. 22 at 1:46 AM

$TNXP is setting up for a $GRAL type move along with $HSCS

0 · Reply

Moneyybaggs Jan. 21 at 10:18 PM

$HSCS Announce those contracts Simpson!!!

0 · Reply

Moneyybaggs Jan. 21 at 9:13 PM

$HSCS Bought 3K more shares myself.

0 · Reply

Moneyybaggs Jan. 21 at 9:03 PM

$HSCS Nice close!!!!

0 · Reply

DrTampa Jan. 21 at 9:03 PM

$HSCS grabbed a few before close as The action was starting to get spicy if you were watching it like I was

0 · Reply

Market Cap	2.27M
Revenue (ttm)	20,000.00
Net Income (ttm)	-6.61M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	11,938
Avg Vol	455,542
Day's Range	N/A - N/A
Shares Out	656,000.00
Stochastic %K	24%
Beta	3.16
Analysts	Strong Sell
Price Target	$13.50